Silo Pharma, Inc., a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, has entered into a research and development agreement to study and develop a dosage and time-release ketamine implant for the treatment of fibromyalgia. A company spokesperson told Contract Pharma that the R&D agreement is with a company headquartered in Sweden with product development and regulatory affairs offices in the Netherlands and a product deve...